Dr Silvia Marsoni and Prof Filippo de Braud discuss the key research that has stood out from ASCO 2010, including PI3K, ERK, BRAF, MEK and TOR and inhibitors. Dr Marsoni goes on to explain why it was important that the results presented at this years conference were not exclusively from successful trials, and talks about what we can learn from negative results. Dr Marsoni and Prof de Braud speculate which cancers could be successfully treated with ipilimumab, and discuss the results of a trial into the use of ALK to treat non-small cell lung cancer.